论文部分内容阅读
目的观察安福隆联合鳖甲软肝丸治疗代偿期肝硬化的临床疗效。方法选择68例代偿期肝硬化患者,随机分为两组,对照组35例采用常规安福隆治疗,治疗组33例在常规治疗基础上加鳖甲软肝丸,观察治疗前后两组患者的临床症状、体征、肝功以及肝纤维化相关指标。结果两组均能明显改善患者临床症状,但以治疗组为优(P<0.05),治疗组患者ALT、AST、GGT、TBIL、PCⅢ(Ⅲ前胶原)、ZV-C(ZV型前胶原)、HA(透明质酸)、LN(层粘连蛋白)、均明显降低,且显著优于对照组(P<0.05或0.01),彩色多普勒显示两组患者治疗后门静脉内径、血流量值皆明显下降,但差异无统计学意义(P>0.05)。结论鳖甲软肝丸联合安福龙能较好的改善代偿期肝硬化患者的临床症状,且对阻断和逆转肝硬化进展有一定疗效。
Objective To observe the clinical efficacy of An Fulong combined with Biejiarangan Pills in the treatment of decompensated cirrhosis. Methods Sixty-eight patients with decompensated cirrhosis were randomly divided into two groups. 35 patients in the control group were treated with conventional An Fulong. 33 patients in the treatment group were treated with Biejia Ruangan Wan on the basis of routine treatment. The patients in both groups before and after treatment Clinical symptoms, signs, liver function and related indicators of liver fibrosis. Results The clinical symptoms of both groups were significantly improved, but the treatment group was superior (P <0.05). The ALT, AST, GGT, TBIL, PCⅢ (procollagen), ZV-C , HA (hyaluronic acid) and LN (laminin) were significantly lower than those of the control group (P <0.05 or 0.01). The color Doppler imaging showed that the diameter of the portal vein, the blood flow value Were significantly decreased, but the difference was not statistically significant (P> 0.05). Conclusion Biejiarangan pills combined with An Fu Long can better improve the clinical symptoms of patients with decompensated cirrhosis, and to block and reverse the progress of cirrhosis have a certain effect.